Neurology:2017年和2010年修订的McDonald标准在预测临床孤立综合征后MS诊断中的表现

2021-10-30 Naomii MedSci原创

2017年McDonald标准相较于2010年McDonald标准,预测CDMS方面显示出更高的敏感性、更低的特异性、相似的准确性,且缩短MS的诊断时间,更准确区分了CIS术后早期患者CDMS。

      2001年,MRI被正式纳入多发性硬化症(MS)诊断标准,以显示多发性硬化症病变的空间扩散(DIS)和时间扩散(DIT)。随后McDonald标准的更新简化了多发性硬化症的诊断,同时保持了敏感性、特异性和准确性。McDonald标准缩短了患有临床隔离综合征(CIS)的患者从出现症状到诊断MS的时间,而不需要等待第二次临床事件的发生。这一点至关重要,因为越来越多的治疗方法已经被证明在有利地改变MS病程方面是有效的,特别是在早期开始的情况下。

      最近,关于MRI和CSF分析在多发性硬化症诊断中的应用的新证据已经出现。MAGNIMS网络在2016为DIS提出了修正的磁共振成像标准。这些循证建议的性能在一项大型的多中心MAGNIMS研究中进行了评估,该研究为2017年修订的MS诊断标准提供了信息,包括消除有症状和无症状病变之间的区别,以及在DIS中合并皮质和旁皮质病变(数据可从Dryad:表e-1 https://doi.org/10.5281/zenodo.5566178).获得。此外,在符合DIS标准的CIS患者中,脑脊液特异性寡克隆带(OCB)的存在可以在没有DIT的临床或磁共振证据的情况下诊断为MS(来自Dryad:Table e-1 https://doi.org/10.5281/zenodo.5566178).的数据)。MAGNIMS网络提出了一个额外的修改,以提高标准的特异性,但未包括在2017年修订中,即将建立脑室周围受累所需的病变数量从1个增加到3个。发表后,几项研究比较了2017年和2010年修订的McDonald标准在9-14岁的成年人和儿童CIS患者中的表现。全球范围内,他们显示2017年McDonald标准在预测临床明确(CD)MS方面比2010年的标准具有更高的敏感性,但特异性较低,但MS诊断时间更短。

      与2017年修订的McDonald标准的表现相关的几个方面仍需充分评估。这些标准的表现主要是在CIS患者的小的、单中心性队列中进行评估的。使用了不同的结果,包括在相对较短或不同的随访后,或者通过结合临床(CDMS)和MRI(新病变)状态来评估CDMS。此外,一些重要的方面只被部分地探索过。这些包括年龄和CIS地形对标准表现的影响,以及治疗开始对发生CDMS的风险的影响。最后,2017年修订版预测残疾累积的能力尚未得到调查。近日,有研究人员比较了2017年修订的McDonald标准和2010年修订的McDonald标准在诊断多发性硬化症(MS)临床孤立综合征(CIS)患者和预测预后方面的表现。

       对来自欧洲9个中心的785例脑梗死患者在发病5个月后进行脑脊液检查、脑和脊髓磁共振检查,并对发病15个月内的≤进行随访。还收集了第二次临床发作的日期和达到扩展残疾状态评分(≥)3.0时的日期(如果发生的话)。2017年和2010年McDonald空间传播标准(DIS)、时间传播标准(DIT)(包括寡克隆条带评估)和DIS+DIT预测第二次临床发作(临床明确[CD])的执行情况MS)和EDSS≥3.0进行随访评估。对不同标准的多发性硬化症的诊断时间也进行了估计。

  • 随访时(中位数为69.1个月),406/785名CIS患者发展为CDMS。
  • 在36个月时,2017年DIS+DIT标准具有较高的敏感性(0.83比0.66)、较低的特异性(0.39比0.60)和相近的曲线下面积值(0.61比0.63)。
  • 与2010年或CDMS标准相比,2017年MS诊断的中位时间更短(2017年修订=3.2;2010年修订=13.0;CDMS=58.5个月)。
  • 这两套标准类似地预测了EDSS≥3.0的里程碑。
  • 在≥45岁的患者中,3个脑室周围病变提高了特异性。

      与2010年的McDonald标准相比,2017年的McDonald标准在预测CDMS方面显示出更高的敏感性、更低的特异性和相似的准确性,同时缩短了MS的诊断时间。这项研究提供了II类证据,表明与2010年的麦当劳标准相比,2017年的McDonald标准更准确地区分了CIS术后早期患者的CDMS。

文献来源:https://n.aan.80599.net/content/early/2021/10/28/WNL.0000000000013016

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2001587, encodeId=3f88200158e88, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Tue May 10 17:57:45 CST 2022, time=2022-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1432178, encodeId=848414321e809, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Mon Nov 01 12:57:45 CST 2021, time=2021-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469432, encodeId=9a7f1469432f4, content=<a href='/topic/show?id=9d6522e613' target=_blank style='color:#2F92EE;'>#ALD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2276, encryptionId=9d6522e613, topicName=ALD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64f67025397, createdName=zhangjingnwpu, createdTime=Mon Nov 01 12:57:45 CST 2021, time=2021-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1065472, encodeId=dee710654e22d, content=好的很,不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b0455598838, createdName=ms9000002102993139, createdTime=Sun Oct 31 09:43:00 CST 2021, time=2021-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1065450, encodeId=c8be106545035, content=完善输注原则,优先选择ABO和RhD同型, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIrrxxDxnLic8t6EAs38Qfwo6H2h6JMleIgb9OSYf6LMnVDkQEqUXWoSDWboibjhOBI9SJDTXweqQIA/132, createdBy=50aa5321359, createdName=查查佳佳, createdTime=Sun Oct 31 08:25:26 CST 2021, time=2021-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1065448, encodeId=07f3106544883, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=58c55294961, createdName=1487042cm12暂无昵称, createdTime=Sun Oct 31 08:25:15 CST 2021, time=2021-10-31, status=1, ipAttribution=)]
    2022-05-10 yinhl1978
  2. [GetPortalCommentsPageByObjectIdResponse(id=2001587, encodeId=3f88200158e88, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Tue May 10 17:57:45 CST 2022, time=2022-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1432178, encodeId=848414321e809, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Mon Nov 01 12:57:45 CST 2021, time=2021-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469432, encodeId=9a7f1469432f4, content=<a href='/topic/show?id=9d6522e613' target=_blank style='color:#2F92EE;'>#ALD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2276, encryptionId=9d6522e613, topicName=ALD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64f67025397, createdName=zhangjingnwpu, createdTime=Mon Nov 01 12:57:45 CST 2021, time=2021-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1065472, encodeId=dee710654e22d, content=好的很,不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b0455598838, createdName=ms9000002102993139, createdTime=Sun Oct 31 09:43:00 CST 2021, time=2021-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1065450, encodeId=c8be106545035, content=完善输注原则,优先选择ABO和RhD同型, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIrrxxDxnLic8t6EAs38Qfwo6H2h6JMleIgb9OSYf6LMnVDkQEqUXWoSDWboibjhOBI9SJDTXweqQIA/132, createdBy=50aa5321359, createdName=查查佳佳, createdTime=Sun Oct 31 08:25:26 CST 2021, time=2021-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1065448, encodeId=07f3106544883, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=58c55294961, createdName=1487042cm12暂无昵称, createdTime=Sun Oct 31 08:25:15 CST 2021, time=2021-10-31, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2001587, encodeId=3f88200158e88, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Tue May 10 17:57:45 CST 2022, time=2022-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1432178, encodeId=848414321e809, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Mon Nov 01 12:57:45 CST 2021, time=2021-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469432, encodeId=9a7f1469432f4, content=<a href='/topic/show?id=9d6522e613' target=_blank style='color:#2F92EE;'>#ALD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2276, encryptionId=9d6522e613, topicName=ALD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64f67025397, createdName=zhangjingnwpu, createdTime=Mon Nov 01 12:57:45 CST 2021, time=2021-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1065472, encodeId=dee710654e22d, content=好的很,不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b0455598838, createdName=ms9000002102993139, createdTime=Sun Oct 31 09:43:00 CST 2021, time=2021-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1065450, encodeId=c8be106545035, content=完善输注原则,优先选择ABO和RhD同型, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIrrxxDxnLic8t6EAs38Qfwo6H2h6JMleIgb9OSYf6LMnVDkQEqUXWoSDWboibjhOBI9SJDTXweqQIA/132, createdBy=50aa5321359, createdName=查查佳佳, createdTime=Sun Oct 31 08:25:26 CST 2021, time=2021-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1065448, encodeId=07f3106544883, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=58c55294961, createdName=1487042cm12暂无昵称, createdTime=Sun Oct 31 08:25:15 CST 2021, time=2021-10-31, status=1, ipAttribution=)]
    2021-11-01 zhangjingnwpu
  4. [GetPortalCommentsPageByObjectIdResponse(id=2001587, encodeId=3f88200158e88, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Tue May 10 17:57:45 CST 2022, time=2022-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1432178, encodeId=848414321e809, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Mon Nov 01 12:57:45 CST 2021, time=2021-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469432, encodeId=9a7f1469432f4, content=<a href='/topic/show?id=9d6522e613' target=_blank style='color:#2F92EE;'>#ALD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2276, encryptionId=9d6522e613, topicName=ALD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64f67025397, createdName=zhangjingnwpu, createdTime=Mon Nov 01 12:57:45 CST 2021, time=2021-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1065472, encodeId=dee710654e22d, content=好的很,不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b0455598838, createdName=ms9000002102993139, createdTime=Sun Oct 31 09:43:00 CST 2021, time=2021-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1065450, encodeId=c8be106545035, content=完善输注原则,优先选择ABO和RhD同型, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIrrxxDxnLic8t6EAs38Qfwo6H2h6JMleIgb9OSYf6LMnVDkQEqUXWoSDWboibjhOBI9SJDTXweqQIA/132, createdBy=50aa5321359, createdName=查查佳佳, createdTime=Sun Oct 31 08:25:26 CST 2021, time=2021-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1065448, encodeId=07f3106544883, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=58c55294961, createdName=1487042cm12暂无昵称, createdTime=Sun Oct 31 08:25:15 CST 2021, time=2021-10-31, status=1, ipAttribution=)]
    2021-10-31 ms9000002102993139

    好的很,不错

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2001587, encodeId=3f88200158e88, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Tue May 10 17:57:45 CST 2022, time=2022-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1432178, encodeId=848414321e809, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Mon Nov 01 12:57:45 CST 2021, time=2021-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469432, encodeId=9a7f1469432f4, content=<a href='/topic/show?id=9d6522e613' target=_blank style='color:#2F92EE;'>#ALD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2276, encryptionId=9d6522e613, topicName=ALD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64f67025397, createdName=zhangjingnwpu, createdTime=Mon Nov 01 12:57:45 CST 2021, time=2021-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1065472, encodeId=dee710654e22d, content=好的很,不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b0455598838, createdName=ms9000002102993139, createdTime=Sun Oct 31 09:43:00 CST 2021, time=2021-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1065450, encodeId=c8be106545035, content=完善输注原则,优先选择ABO和RhD同型, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIrrxxDxnLic8t6EAs38Qfwo6H2h6JMleIgb9OSYf6LMnVDkQEqUXWoSDWboibjhOBI9SJDTXweqQIA/132, createdBy=50aa5321359, createdName=查查佳佳, createdTime=Sun Oct 31 08:25:26 CST 2021, time=2021-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1065448, encodeId=07f3106544883, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=58c55294961, createdName=1487042cm12暂无昵称, createdTime=Sun Oct 31 08:25:15 CST 2021, time=2021-10-31, status=1, ipAttribution=)]
    2021-10-31 查查佳佳

    完善输注原则,优先选择ABO和RhD同型

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=2001587, encodeId=3f88200158e88, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Tue May 10 17:57:45 CST 2022, time=2022-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1432178, encodeId=848414321e809, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Mon Nov 01 12:57:45 CST 2021, time=2021-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469432, encodeId=9a7f1469432f4, content=<a href='/topic/show?id=9d6522e613' target=_blank style='color:#2F92EE;'>#ALD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2276, encryptionId=9d6522e613, topicName=ALD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64f67025397, createdName=zhangjingnwpu, createdTime=Mon Nov 01 12:57:45 CST 2021, time=2021-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1065472, encodeId=dee710654e22d, content=好的很,不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b0455598838, createdName=ms9000002102993139, createdTime=Sun Oct 31 09:43:00 CST 2021, time=2021-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1065450, encodeId=c8be106545035, content=完善输注原则,优先选择ABO和RhD同型, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIrrxxDxnLic8t6EAs38Qfwo6H2h6JMleIgb9OSYf6LMnVDkQEqUXWoSDWboibjhOBI9SJDTXweqQIA/132, createdBy=50aa5321359, createdName=查查佳佳, createdTime=Sun Oct 31 08:25:26 CST 2021, time=2021-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1065448, encodeId=07f3106544883, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=58c55294961, createdName=1487042cm12暂无昵称, createdTime=Sun Oct 31 08:25:15 CST 2021, time=2021-10-31, status=1, ipAttribution=)]
    2021-10-31 1487042cm12暂无昵称

    学习

    0

相关资讯

JNNP:多发性硬化症患者对SARS-CoV-2 mRNA疫苗的体液免疫

虽然多发性硬化症(pwMS)患者本身不会增加SARS-CoV-2感染或严重CoV-19疾病的风险,但是i因为存在共病、较高年龄、MS相关残疾、和某些疾病改良疗法(DMT)持续治疗的情况下,感染风险会升

Neurology:多发性硬化,大脑网络有何变化

FC异常伴随着局部脑血流和结构连接的异常,

Lancet Neurol:口服脑穿透性BTK抑制剂托莱布替尼治疗复发性多发性硬化症的安全性和有效性?

急性炎症的减少,再加上调节中枢神经系统内免疫反应的可能性,为托莱布替尼在复发性和进展性多发性硬化症患者中进行3期临床试验提供了科学依据。

Lancet Neurol:无功无过——间充质干细胞与安慰剂治疗多发性硬化症(MESEMS)的安全性、耐受性和活性的研究

骨髓来源的MSC治疗是安全的,耐受性良好,但对活动性多发性硬化症患者第24周的GELs没有影响因此,本研究不支持使用骨髓间充质干细胞治疗活动性多发性硬化症。

Neurology:青春期和青春期体重指数与多发性硬化症长期风险的关系:一项基于人群的研究

多发性硬化症(MS)是一种慢性、炎性和脱髓鞘的中枢神经系统(CNS)疾病,通常影响年轻人。无论是男性还是女性,14-24岁的高BMI与晚年患多发性硬化症的风险增加有关。

Lancet Neurol:耐受性差,疗效阴性——不推荐贝沙罗汀治疗复发缓解型多发性硬化症(CCMR ONE)

研究不推荐使用贝沙罗汀治疗多发性硬化症患者,因为它的耐受性差,主要疗效结果为阴性。

拓展阅读

Lancet Child Adol Health:儿童及青少年多发性硬化诊断特征研究

研究发现,2017 McDonald多发性硬化诊断标准对儿童MS患者诊断表现出良好的准确性。脑脊液寡克隆检查大大提高了诊断的准确性。髓鞘少突胶质糖蛋白抗体检测可鉴别急性播散性脑脊髓炎和复发性非多发性硬化患儿